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Abstract
Introduction. Adult pelvic soft tissue sarcomas are a rare group of heterogeneous malignancies. These sarcomas differ from
extremity and trunk soft tissue sarcomas in presentation, characteristics and response to treatment.
Methods. A retrospective analysis of patient and tumor characteristics, treatment and prognosis and prognostic factors was
performed.
Results. Between 1977 and 1997, a total of 33 adult patients with soft tissue sarcomas involving the pelvis but excluding
uterine leiomyosarcoma were identified. Leiomyosarcomas (18), including six GIST, and rhabdomyosarcomas (eight) were
the most commonly seen tumors. At first presentation, nine patients already had metastases. The mean follow-up was
52 months (1–200). Recurrences developed in 15 of the 24 cases (63%) with tumors without metastases at first presentation;
in six (25%) recurrence was locally only, in nine distant metastases occurred. The nine patients with metastatic disease
at first presentation died of the disease, while eight of the 24 patients with localized disease at presentation died. One patient
died of an unrelated cause, four were alive with disease, and 11 patients were alive and free of disease. The only identifiable
prognostic factor of disease-free interval and overall survival was histological grade.
Conclusion. Soft tissue sarcomas of the pelvis appear to be associated with increased rate of metastasis at the time of diagnosis
and higher rates of local recurrence. In this study, multi-modality treatment for most primary tumors did not show a
significant benefit in recurrence rate, DFI and OST, when compared to single modality approach. Although the number of
patients in this study is small, and different types of sarcomas were studied, the only identifiable predictor for survival was
low histological grade of the tumors. The differences of this heterogeneous group of pelvic sarcomas with retroperitoneal,
trunk and extremity sarcomas should be taken into consideration in the management of these sarcomas.
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Introduction
Less than 5% of all sarcomas are located in the pelvic
region and the majority of these are related to the
genitourinary tract.
1,2 These sarcomas may not
produce symptoms until they are large and have
extensively invaded local tissues.
3 Local and distant
recurrent disease is a major problem, resulting in
a high disease-related mortality rate.
1 Previous
studies have demonstrated that surgery offers the
most effective treatment for adult sarcoma of
the pelvis.
2,3 However, anatomical constraints of the
pelvis and early involvement of adjacent structures
often mean that excision margins in most cases are
marginal.
3 Adjuvant radiotherapy and chemotherapy
in adult patients with STS of the pelvis have not
improved overall survival, but may have effect on
local control.
2,3 This study of patients with STS of
the pelvis was performed to evaluate the character-
istics and the results of treatment.
Methods
We collected data from all adult patients with a
diagnosis of soft tissue sarcoma of the pelvic region
from 1977 to 1997 treated at the NKI/AvL retro-
spectively.
These included sarcomas of the genitourinary and
digestive tract as far as they are located around the
pelvis or pelvic floor. Ovarian sarcomas and uterine
sarcomas, including mixed Mu ¨llerian tumors, were
excluded.
A total of 33 patients with soft tissue sarcomas in
the pelvis were identified in the prospective cancer
database in our institute. This represents 6% of the
1415 patients with soft tissue sarcomas seen at our
center over the period of study. In 26 of the 33
patients, we were involved in the primary treatment.
The pathology was reviewed to obtain a uniform
histological classification and grade, according to
actual criteria.
4 Follow-up was noted from the last
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disease-free interval were calculated from the date of
the start of treatment.
Results
Patient characteristics
There were 12 females and 21 males, age ranging
from 16 to 79 years (median age 49 years). The
median age of females was 49 and for men 36 years
(Table 1).
Tumor characteristics
Histological proof of sarcoma was made by large core
needle biopsy or incisional biopsy in 14 patients and
by excisional biopsy in 19 patients.
The most common histological types were leio-
myosarcoma (LMS) (18 patients, including six
gastrointestinal stromal cell tumors of the rectum)
and rhabdomyosarcoma (RMS) (eight, including
four embryonal and four other sub-types). Two
liposarcomas (LPS), two malignant fibrous histio-
cytomas (MFH), one dermatofibrosarcoma protube-
rans (DFSP), one epithelioid sarcoma (ECS) and one
sarcoma not otherwise specified (SNOS) were seen.
The site of the tumor, relation to deep fascia,
histological grade and presence or absence of meta-
stases at presentation are shown in Table 2.
The median size of tumor was 5cm (range
2–13cm). Most tumors were related to the male
(16) or female (eight) urogenital tract; eight tumors
originated in or were adjacent to the rectal wall and
one was in the pelvic venous plexus. Most tumors
were deep to the fascia (30/33), were intermediate to
high grade (31/33) and in nine patients metastatic
disease was established at the moment of diagnosis
(Table 2).
Treatment characteristics
Primary therapy consisted of single modality treat-
ment in 15 cases and multi-modality therapy in 18
patients, as specified in Table 3. Our institution was
involved in (part of) the primary treatment in 26 of
33 patients.
Six of eight patients with RMS (including three
with primary metastatic disease) were treated by
multi-modality approach, as were nine patients
with LMS (no primary metastatic disease). Two of
the primary metastatic RMS patients were treated
by single modality only (chemotherapy), as were
the other nine patients with LMS (two with primary
metastatic disease).
Primary metastatic disease was thus treated by
multi-modality approach in four and by single
modality approach in five patients. In these nine
patients presenting with metastatic disease, surgery
(four), radiotherapy (four) and chemotherapy (five)
were applied almost equally.
All 24 patients with localized disease had surgical
excision, combined with radiotherapy in 12 and
chemotherapy in three patients.
Resection margins were wide in eight patients,
marginal in 10 cases and intralesional (debulking) in
10 cases.
Table 1. Patients, median age, histological classification
Total Male Female Median age (years)
Patients (N)3 3 2 1 1 2
Median age (range) 36 (16–79) 49 (36–76) 49 (16–79)
Histology
Embryonal rhabdomyosarcoma 4 4 0 17
Other rhabdomyosarcoma 4 4 0 20
Leiomyosarcoma (non-GIST) 12 7 5 59
Leiomyosarcoma (GIST) 6 4 2 51
Malignant fibrous histiocytoma 2 0 2 59
Myxoid liposarcoma 2 1 1 34
Epithelioid sarcoma 1 0 1 37
Dermatofibrosarcoma 1 0 1 49
Sarcoma n.o.s. 1 1 0 50
Table 2. Localisation, relation to the fascia,

















Local disease only 24
Primary metastasized 9
20 C. M. G. Keyzer-Dekker et al.Radiotherapy doses varied between 16 and 66 Gy,
depending on the purpose of the treatment. As
adjuvant therapy after resection with tumor-free
margins, 60 Gy was considered sufficient. After
incomplete surgery, radiotherapy with a boost up to
66 Gy was administered.
Chemotherapy treatment included administra-
tion of several drugs: actinomycin A, adriamycin,
etoposide, ifosfamide and vincristine in different
combinations. Primary chemotherapy was chosen as
treatment modality in five of nine cases presenting
with disseminated disease.
Complications of treatment
Primary treatment of these 33 patients was unevent-
ful in 26 of 33 patients (79%). Single modality
treatment (15 patients) was correlated to two
eventful courses; one patient developed a sepsis
under chemotherapy and in another patient osteo-
myelitis of the pubic bone occurred after radical
vulvectomy. Multi-modality treatment (18 patients)
was uneventful in 13 patients (72%). Nausea,
impotence and three cases of hematoma were seen
(Table 3).
Local and distant failure
Nine patients had metastatic disease at presentation.
All progressed on treatment or responded for short
periods. Of the 24 patients with localized disease
at presentation, 15 (63%) recurred after primary
treatment.
The two low-grade tumors (one LPS and one
DFSP) did not recur or metastasize; 10 of 12 grade II
(83%) and five of 10 grade III (50%) recurred.
Local recurrence as first presentation of recurrent
disease was seen in six of the 24 patients. Multiple
local recurrences were seen in one patient with a
myxoid liposarcoma. After wide or marginal surgery,
sarcoma recurred in 10 of 16 patients, and after
intralesional surgery in five of eight patients. The
average time to local recurrence was 19 months.
Pulmonary metastatic disease occurred in five of
24 patients, while in six patients extrapulmonary sites
of metastases were seen as first manifestation of
metastatic disease. The average time to pulmonary
metastases was 13 months, and to extrapulmonary
distant disease this was 22 months. Two patients
with pulmonary metastases had resection of the
metastases and one of these patients survived for
more than 2 years.
Of the six patients with extrapulmonary metas-
tases, two with GIST underwent partial liver resec-
tion and both survived for more than 5 years after
liver resection.
One patient with extrapulmonary metastatic
disease had a long-term survival (>5 years) after
combination of chemo- and radiotherapy. One of our
patients who had multiple resections of metastatic
disease is still alive without disease activity as a result
of Imatinib treatment.
Patients without metastases at presentation
There was a difference in DFI between RMS
(two patients, mean interval 9 months) and LMS
(10 patients, mean interval 27 months) (P¼0.36).
Table 4 shows the DFI in relation to histology,
grade, surgical margins and treatment modality.
Survival time and prognostic factors
In this study, the actuarial 5-year survival was 33%.
The median overall survival in this study was 45
months, range 1–200 months. At the last follow-up,
17 of 33 patients had died of the disease (DOD),
four of 33 were alive with evidence of disease (ED),
11 alive without evidence of the disease (NED) and
one patient died of unrelated cause (UND).
Table 3. Histology, type of treatment, complications and survival
Single disciplinary treatment Multi-disciplinary treatment
Histology RMS 2 RMS 6
LMS 9 LMS 9
Other 4 Other 3
Treatment Surgery 12 Surgery/Radiotherapy 11
Radiotherapy 1 Surgery/Chemotherapy 4
Chemotherapy 2 Chemotherapy/Radiotherapy 2
Surgery/radiotherapy/chemotherapy 1
Complications Osteomyelitis (surg related) 1 Haematoma (surg related) 3
Sepsis (chemo related) 1 Nausea (chemo related) 1
Impotence (surg plus radio related) 1
Survival NED 5 (33%) NED 6 (33%)
ED 2 (13%)E D 2 ( 11%)
DOD 8 (54%) DOD 9 (50%)
UND 1 (6%)
Abbreviations: RMS, rhabdomyosarcoma; LMS, leiomyosarcoma; NED, no evidence of disease; ED, evidence of disease; DOD, died of
disease; UND, unrelated death.
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treated with surgery and radiotherapy was 62 months
(range 5–112); for 15 patients treated with surgery
only, the overall survival time was 116 months
(range 9–200) (P¼0.73). The mean disease-free
interval after surgery and radiotherapy was 11
months, and this was 25 months (P¼0.39) after
surgery alone.
After surgery and radiotherapy, six of 13 patients
had a recurrence; after surgery, 12 of 15 patients had
a recurrence (P¼0.06). The overall survival time in
patients with localized disease was 105 months in
patients (nine) without recurrence and 113 months
with recurrence (15).
The influence of non-metastatic disease on sur-
vival was analysed for histology, grade, surgical
margins and treatment modality (Table 4). None of
the factors analysed was statistically significant.
Discussion
Sarcomas located in the pelvic region are rare, the
number of relevant studies are limited and the
inclusion criteria show major differences, therefore
comparisons with other studies are difficult.
In this study, LMS and RMS formed the majority
of all cases. An analysis of two so different types of
tumor has great limitations. RMS and LMS are seen
at different decades of life. RMS is always a high
grade tumor that presents in adolescents, often
already with metastatic disease. Moreover, their
treatment may differ since many of these young
adults with RMS will be subjected to treatment
according to childhood and young adolescent regi-
mens. LMS, however, is often seen in adults, and
presents usually as local disease only, on which the
treatment often is focused.
Our study, however, compares well with a study of
43 patients treated in MSKCC.
2 The most common
histological types in the MSKCC study were also
LMS (17) and RMS (13), there were five low grade
tumors and 31 high grade tumors (if we exclude
the seven patients with kidney tumors in that study).
In the MSKCC study nine of 43 presented with
metastatic disease, almost all (8/9) with RMS. Where
in that study only two of the nine patients survived
(both RMS), all patients with primary metastatic
disease in our study died with a mean OST of 17
months. Presentation with metastatic disease can
therefore be concluded to be a poor prognostic
factor.
Analogous to childhood RMS, treatment of RMS
usually consists of a combination of chemotherapy
and local treatment. Combination treatment in
metastatic disease in our young adults, however,
showed no ultimate beneficial effect. Chemotherapy-
based treatment in the three others with local RMS
only resulted in one long-term survivor, and death
from disease 12 months after start of treatment
in a second patient. Another long-term survivor
with RMS had local combination treatment only.
The value of chemotherapy-based treatment in this
study thus remains unclear.
A possible major difference in treatment outcome,
even in metastatic disease, however, is now emerging
in another subgroup. As one of our patients has
experienced, the introduction of tyrosine kinase
inhibitors such as Imatinib may change the prognosis
of patients with GIST even, or in particular, when
this disease has metastasized.
18
We have analyzed the effect of single versus multi-
modality treatment on recurrence rate, disease-
free interval and overall survival time. The patients
in these two treatment modality groups were
Table 4. Disease-free interval and overall survival time (mean in months) in primary non-metastatic








RMS 2/3 9 (3–16) 99 (12–142)
LMS 10/16 27 (3–140) 94 (5–159)
Other 3/5 20 (13–32) 164 (18–200)
Grade
Low 0/2 113 (112–115)
Intermediate 10/12 31 (6–140) 123 (12–200)
High 5/10 8 (3–16) 86 (5–142)
Surgical margins
Intralesional 5/8 14 (3–34) 61 (5–112)
Marginal/wide 10/16 28 (3–140) 139 (12–200)
Treatment modality
Single 8/10 35 (6–140) 149 (12–200)
Multi 7/14 10 (3–20) 81 (5–142)
Abbreviations: DFI, disease-free interval; OST, overall survival time; RMS, rhabdomyosarcoma; LMS,
leiomyosarcoma.
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grade 2 tumors in the single modality treatment
group (10/15) and more grade 3 tumors in the multi-
modality treatment group (13/18). But tumor grade
as a single prognostic factor did not reveal statistical
significant differences in survival.
In non-metastatic disease, all patients were treated
by surgery or surgery in combination with radio-
or chemotherapy. Excluding RMS, and independent
of the primary metastatic status, single modality
treatment did not prove to be less effective than
multi-modality treatment on recurrence rate, DFI
and OST.
A sub-analysis revealed that there was no signifi-
cant difference in recurrence rate, DFI and OST
after surgery alone compared with surgery and
radiotherapy. The small number in the subgroups,
however, could partly explain these findings.
While radiotherapy plays a major role in adjuvant
treatment in extremity and trunk sarcomas, and
adjuvant chemotherapy may add to local control,
6–10
in this retrospective study no proof for benefit of
adjuvant treatment was found in primary treatment
of pelvic sarcomas. This confirms findings in pre-
vious studies demonstrating surgery to be the only
effective primary treatment in pelvic sarcomas and
that adjuvant radiotherapy and chemotherapy did
not seem to improve overall survival.
2,3 Although the
role of adjuvant or neoadjuvant chemotherapy in the
treatment of RMS in childhood is indisputable, in
this study and in adulthood it is yet to be proven.
Pelvic surgery is limited because of the early
involvement of adjacent pelvic structures, therefore
surgery is often performed with minimal margins,
which is reflected by the high incidence of local
recurrence. The local recurrence rate seen in this
study was 25% (6/24), and overall recurrence (local
and distant) after primary treatment in patients
with localized disease was seen in 15 of 24 (63%).
Histology, grade (except for the low grade tumors),
surgical margins and treatment modality did not
seem to influence the frequency of recurrence. There
was a high recurrence rate seen in patients with
primary non-metastatic disease; multi-modality
treatment approach, however, proved successful for
these recurrences, considering the prolonged overall
survival time.
The local recurrence rate in extremity and trunk
sarcomas in non-metastatic disease is usually less
than 20% and distant disease is often found first and
mainly as pulmonary metastases.
5 The pathway of
distant metastatic disease in pelvic sarcomas is also
different from extremity sarcomas, since the majority
are non-pulmonary metastases, as six of 11 patients
developed distant metastases located in liver, skeletal
bones or soft tissues.
In the MSKCC study, more low grade sarcomas
were seen and grade and margins were considered
prognostic factors. In that study, 49% died of
disease, 5% were alive with evidence of disease
and 36% were alive with no evidence of disease.
Unlike this study, and unlike extremity and trunk
sarcomas, in our study histology, grade and surgical
margins did not show significant differences in
recurrence rate, DFI and OST. However, we could
not perform a multivariate analysis on prognostic
factors considering the small number of patients
in our study.
In our study the overall 5-year survival was 33%,
which is comparable with previous studies where
20–60% was found.
1
Our findings show resemblance to studies of
retroperitoneal sarcomas, where the late presentation
and frequent invasion of adjacent structures are
also a main problem for achieving complete surgical
resection. The most effective treatment modality
for these tumors is complete surgical resection;
chemotherapy has not proven to be effective and
radiotherapy is limited by toxicity to adjacent
structures. Patients with retroperitoneal sarcomas,
however, often die of uncontrollable recurrent local
disease,
11–13 whereas in this study metastatic disease
was the main factor in fatal outcome. Surgical
management of metastatic disease resulted in long-
term survival in three patients in this study. In
selected cases of pulmonary and liver metastases,
surgical management of metastatic disease can result
in 30–35% 5-year survival.
14–17
Conclusions
Pelvic sarcomas are difficult to diagnose because of
their location, their late presentation and their rarity.
Pelvic sarcomas, although a heterogeneous group of
tumors, have specific characteristics, such as a high
local recurrence rate and a high primary metastatic
presentation rate. Primary metastatic disease proves
to be an important poor prognostic factor, but
adequate treatment of local disease and local
recurrence can still result in a long-term successful
outcome. Therefore it is of clinical importance
that these sarcomas are considered as a possible
diagnosis, despite their rarity in the pelvis!
Due to the heterogeneity of these tumors, the
treatment approach may be various. In this study
multi-modality treatment for most primary tumors
did not show a significant benefit in recurrence rate,
DFI and OST, when compared to single modality
approach.
A prolonged DFI and OST was seen to be related
to low grade only, but the small number of patients
in this study may explain the lack of other prognostic
factors.
The heterogeneity of the different types of
sarcomas makes drawing clear conclusions difficult,
but the differences with retroperitoneal, trunk and
extremity sarcomas should be taken into consider-
ation in the management of pelvic sarcomas.
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